# IBI343 Combined With Sintilimab Plus Chemotherapy in Gastric Cancer

> **NCT07025889** · PHASE1,PHASE2 · RECRUITING · sponsor: **Ruijin Hospital** · enrollment: 55 (estimated)

## Conditions studied

- Gastric Cancer

## Interventions

- **DRUG:** IBI343
- **DRUG:** Sintilimab
- **DRUG:** Oxaliplatin
- **DRUG:** S-1

## Key facts

- **NCT ID:** NCT07025889
- **Lead sponsor:** Ruijin Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-06-02
- **Primary completion:** 2026-06
- **Final completion:** 2028-06
- **Target enrollment:** 55 (ESTIMATED)
- **Last updated:** 2025-06-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07025889

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07025889, "IBI343 Combined With Sintilimab Plus Chemotherapy in Gastric Cancer". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT07025889. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*